Streetbeat News

Regulatory

NVO

Novo Nordisk's shares are trading lower following an announcement by Britain's drug watchdog that it is investigating a class of drugs that includes Novo's diabetes medicine Ozempic and weight-loss treatment Saxenda, due to reports of suicidal thoughts.

Portfolio Pulse from Bill Haddad

July 26, 2023 | 12:40 pm

AZN

EWU

LLY

The UK's Medicines and Healthcare Products Regulatory Agency is reviewing AstraZeneca's diabetes drug Bydureon, Sanofi's Lixisenatide, and Eli Lilly's Dulaglutide.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 12:36 pm

EWU

NVO

Britain's drug watchdog is investigating a class of drugs that includes Novo's diabetes medicine Ozempic and weight-loss treatment Saxenda following reports of suicidal thoughts.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 12:35 pm

AMRN

Amarin Corporation has announced that its latest research on the clinical benefits of VASCEPA/VAZKEPA will be presented at the European Society of Cardiology Congress.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 12:29 pm

BABA

META

Alibaba Group's fintech affiliate, Ant Group, is undergoing a restructuring to focus on its core China financial-related business. The restructuring will see Ant Group eliminate its blockchain, database management services, and international business. Once the restructuring is complete, Ant Group will apply for a financial holding license in China and prepare for an IPO in Hong Kong. Alibaba's cloud computing division has also become the first Chinese enterprise to support MetaPlatforms Inc's open-source AI model Llama.

Portfolio Pulse from Anusuya Lahiri

July 26, 2023 | 12:25 pm

AMRX

Amneal Pharmaceuticals has submitted Abbreviated New Drug Applications (ANDAs) to the U.S. FDA for three complex generics. The drugs include Albuterol sulfate inhalation, Bimatoprost ophthalmic solution, and Propofol emulsion, with U.S. IQVIA sales of $814 million, $779 million, and $311 million respectively.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 12:23 pm

EDAP

EDAP TMS has received approval for reimbursement in Switzerland for the use of its High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer. This approval could potentially increase the adoption of EDAP's HIFU technology in Switzerland.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 12:20 pm

SPY

The number of building permits issued in the US came in at 1.441 million, slightly above the estimated 1.440 million.

Portfolio Pulse from Bill Haddad

July 26, 2023 | 12:09 pm

ABBV

AbbVie has announced the publication of results from its Phase 4 IMMpulse study of SKYRIZI, which achieved all primary and ranked secondary endpoints. This suggests a positive development in the company's drug pipeline.

Portfolio Pulse from Bill Haddad

July 26, 2023 | 12:09 pm

INZY

Inozyme Pharma, Inc. (NASDAQ:INZY) has announced a regulatory update for its global development strategy of INZ-701 for the treatment of ENPP1 Deficiency. The company has finalized its pediatric pivotal trial design with PPi, a natural inhibitor of mineralization, as a primary endpoint in the U.S. and a co-primary endpoint in the EU. The company's updated cash runway is expected to fund cash flow requirements into Q1 2025.

Portfolio Pulse from Charles Gross

July 26, 2023 | 11:52 am